These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 2119264)

  • 1. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
    Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
    Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of antibody specificity in measuring cross-linked fibrin degradation products by ELISA.
    Eisenberg PR; Rylatt DB; Rusticali F; Ferrini D; Ottani F; Galvani M
    Blood Coagul Fibrinolysis; 1997 Mar; 8(2):105-13. PubMed ID: 9518041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction.
    Lawler CM; Bovill EG; Stump DC; Collen DJ; Mann KG; Tracy RP
    Blood; 1990 Oct; 76(7):1341-8. PubMed ID: 2119827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivity of D-dimer assays with the fibrinogen--fibrin split products generated by thrombolytic agents.
    Amiral J; Minard F; Plassart V; Vissac AM; Chambrette B
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):525-30. PubMed ID: 2133230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.
    Francis CW; Connaghan DG; Marder VJ
    Circulation; 1986 Nov; 74(5):1027-36. PubMed ID: 3533310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
    Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
    Thromb Haemost; 1996 Sep; 76(3):339-43. PubMed ID: 8883267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
    Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
    Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
    Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF
    Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
    Koopman J; Haverkate F; Koppert P; Nieuwenhuizen W; Brommer EJ; Van der Werf WG
    J Lab Clin Med; 1987 Jan; 109(1):75-84. PubMed ID: 3540164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation.
    Eisenberg PR; Sherman LA; Tiefenbrunn AJ; Ludbrook PA; Sobel BE; Jaffe AS
    Thromb Haemost; 1987 Feb; 57(1):35-40. PubMed ID: 3109058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of assays for the detection of fibrin(ogen)olysis based on COOH-terminal A alpha chain epitopes.
    Sobel JH; Wu HQ; Canfield RE
    Blood; 1994 Jul; 84(2):535-46. PubMed ID: 7517717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation.
    Brenner B; Francis CW; Totterman S; Kessler CM; Rao AK; Rubin R; Kwaan HC; Gabriel KR; Marder VJ
    Circulation; 1990 Jun; 81(6):1818-25. PubMed ID: 2111742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The detection of D-dimer in plasma by enzyme immunoassay: improved discrimination is obtained with a more specific signal antibody.
    Hart R; Bate I; Dinh D; Elms M; Bundesen P; Hillyard C; Rylatt DB
    Blood Coagul Fibrinolysis; 1994 Apr; 5(2):227-32. PubMed ID: 7519890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system.
    Eisenberg PR; Sobel BE; Jaffe AS
    Circulation; 1988 Sep; 78(3):592-7. PubMed ID: 3136954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.
    Declerck PJ; Mombaerts P; Holvoet P; De Mol M; Collen D
    Thromb Haemost; 1987 Dec; 58(4):1024-9. PubMed ID: 3127914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma.
    Koppert PW; Hoegee-de Nobel E; Nieuwenhuizen W
    Thromb Haemost; 1988 Apr; 59(2):310-5. PubMed ID: 3133813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in the fibrinolytic system components during acute myocardial infarction.
    Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
    Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers.
    Francis CW; Doughney K; Brenner B; Klingbiel K; Marder VJ
    Circulation; 1989 Mar; 79(3):666-73. PubMed ID: 2465100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.